Top 10 Biotech Stocks To Invest In Right Now

Top 10 Biotech Stocks To Invest In Right Now: Receptos Inc (RCPT)

Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company's product candidates span three specialty disease areas. The Company's lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.

As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.

As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company's second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal a! ntibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune- mediated disorder.

Advisors' Opinion:

• [By Jayson Derrick]

  Receptos (NASDAQ: RCPT) announced that its lead product candidate RPC1063 successfully achieved its primary endpoint in a Phase 2 clinical study, which evaluated safety and efficacy for the treatment of ulcerative colitis with a 1 mg dose. Shares surged to new 52-week highs of $102.60 before closing the day at $95.75, up 41.35 percent.

• [By Garrett Cook]

  Receptos (NASDAQ: RCPT) shares shot up 38.62 percent to $93.90 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.

• [By Garrett Cook]

  Receptos (NASDAQ: RCPT) shares shot up 46.35 percent to $99.14 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.

• [By Ben Levisohn]

  Yes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos
  (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-biotech-stocks-to-invest-in-right-now-3.html